Skip to main content
. 2021 Aug 16;10(16):3612. doi: 10.3390/jcm10163612

Figure 3.

Figure 3

Figure 3

Forest plot of the efficacy of PD-1/PD-L1 inhibitor use in esophageal or G/GEJ cancer patients: (a) Overall PFS; (b) Subgroup analysis comparison between anti-PD-1 and PD-L1 of PFS; (c) Subgroup analysis of individual agents of PFS; (d) Subgroup analysis of treatment line of PFS; (e) Subgroup analysis of tumor site of PFS (AVE: avelumab; CAM: camrelizumab; G/GEJ: gastric and gastroesophageal junction; NIV: nivolumab; PEM: pembrolizumab; PD-1: PD-1 inhibitor; PD-L1: PD-L1 inhibitor).